Amgen’s (AMGN) Blincyto Gets FDA Nod for Consolidation Treatment
ZacksAmgen’s (AMGN) Blincyto is now approved for the treatment of adult and pediatric patients one month and older with Philadelphia chromosome-negative B-ALL in the consolidation phase, regardless of MRD status.